本帖最后由 老马 于 2012-1-13 21:20 编辑 % L) C/ @: y" Z A4 l
. H: B$ g! F$ b; |1 n: |+ h; S( ]爱必妥和阿瓦斯丁的比较! Q% T, L; I& |( e- T7 ~
/ Z: W/ a9 L- Q3 [& x) Phttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
9 Q! D' \. e/ q& N' D3 l
) d' a: y* }& J! {( q: S9 h0 M' ]
" a& h3 b x$ K6 W0 G' d5 yhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
# J2 o; @9 g, L* |$ e% T( ?==================================================
- h+ B3 P W$ G9 rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 [; j6 [/ j& E' {
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
% m- ]7 f1 R. M; p' wResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.9 g' g5 m7 F* m5 }3 p
|